Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
出版年份 2018 全文链接
标题
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
作者
关键词
-
出版物
NATURE MEDICINE
Volume 24, Issue 2, Pages 203-212
出版商
Springer Nature
发表日期
2018-01-16
DOI
10.1038/nm.4472
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance
- (2017) Sydney M. Shaffer et al. NATURE
- Translation rewiring at the heart of phenotype switching in melanoma
- (2017) Eleonora Leucci et al. Pigment Cell & Melanoma Research
- New developments for antibody-drug conjugate-based therapeutic approaches
- (2016) Bart ECG de Goeij et al. CURRENT OPINION IN IMMUNOLOGY
- Antibody–drug conjugates for cancer therapy
- (2016) Anish Thomas et al. LANCET ONCOLOGY
- Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials
- (2016) Georgina V Long et al. LANCET ONCOLOGY
- Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
- (2016) Heather Donaghy mAbs
- A combinatorial strategy for treating KRAS-mutant lung cancer
- (2016) Eusebio Manchado et al. NATURE
- Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition
- (2016) Aaron N Hata et al. NATURE MEDICINE
- Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
- (2016) I. Tirosh et al. SCIENCE
- Reprogramming the immunological microenvironment through radiation and targeting Axl
- (2016) Todd A. Aguilera et al. Nature Communications
- Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance
- (2016) M. A. Miller et al. Cancer Discovery
- Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy
- (2016) Helen Creedon et al. Oncotarget
- Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling
- (2016) Cun Wang et al. Theranostics
- BRAF V600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts
- (2016) Kristel Kemper et al. Cell Reports
- AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
- (2015) Moshe Elkabets et al. CANCER CELL
- A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition
- (2015) M. P. Mak et al. CLINICAL CANCER RESEARCH
- Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts
- (2015) K. Kemper et al. EMBO Molecular Medicine
- Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma
- (2015) Patrick Reichl et al. HEPATOLOGY
- CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin
- (2015) R. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Studying clonal dynamics in response to cancer therapy using high-complexity barcoding
- (2015) Hyo-eun C Bhang et al. NATURE MEDICINE
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data
- (2015) Antonio Colaprico et al. NUCLEIC ACIDS RESEARCH
- ALK inhibitor resistance in ALKF1174L-driven neuroblastoma is associated with AXL activation and induction of EMT
- (2015) D N Debruyne et al. ONCOGENE
- Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
- (2015) L Zhou et al. ONCOGENE
- Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib
- (2015) Wei Xu et al. Cell and Bioscience
- Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer
- (2014) Helen Creedon et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- MAPK Pathway Inhibition Enhances the Efficacy of an Anti-Endothelin B Receptor Drug Conjugate by Inducing Target Expression in Melanoma
- (2014) J. Asundi et al. MOLECULAR CANCER THERAPEUTICS
- No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients
- (2014) Maria Romina Girotti et al. Molecular Oncology
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
- (2014) Judith Müller et al. Nature Communications
- The Immune Microenvironment Confers Resistance to MAPK Pathway Inhibitors through Macrophage-Derived TNF
- (2014) M. P. Smith et al. Cancer Discovery
- A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors
- (2014) D. J. Konieczkowski et al. Cancer Discovery
- An Antibody-Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors
- (2013) E. C. W. Breij et al. CANCER RESEARCH
- Cisplatin influences acquisition of resistance to molecular-targeted agents through epithelial-mesenchymal transition-like changes
- (2013) Maki Kurokawa et al. CANCER SCIENCE
- A simple, robust and highly efficient transient expression system for producing antibodies
- (2013) Tom Vink et al. METHODS
- The Implications of Clonal Genome Evolution for Cancer Medicine
- (2013) Samuel Aparicio et al. NEW ENGLAND JOURNAL OF MEDICINE
- The receptor tyrosine kinase Axl regulates cell–cell adhesion and stemness in cutaneous squamous cell carcinoma
- (2013) M A Cichoń et al. ONCOGENE
- Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
- (2013) H. Shi et al. Cancer Discovery
- An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
- (2012) L. A. Byers et al. CLINICAL CANCER RESEARCH
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2012) Mathew J. Garnett et al. NATURE
- The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
- (2012) Luis A. Diaz Jr et al. NATURE
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
- (2010) Sreenath V. Sharma et al. CELL
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Analysis of the genome to personalize therapy for melanoma
- (2010) M A Davies et al. ONCOGENE
- Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6
- (2009) S. Loges et al. BLOOD
- Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia
- (2008) Chih-Chen Hong et al. CANCER LETTERS
- In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States
- (2008) K. S. Hoek et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started